Phase 2 Type 2 diabetes trials recruiting now

All Type 2 diabetes trials, every phase

Other phases for Type 2 diabetes

Phase 2 Type 2 diabetes trials

• A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus
  NCT06937203 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 16 locations
• A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus
  NCT06700538 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 7 locations
• A Mechanistic Study on the Effect of HTD1801 Versus Placebo on Kidney Function in Patients With Type 2 Diabetes and Chronic Kidney Disease.
  NCT07496177 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes
  NCT07061574 · Phase: Phase 1, Phase 2 · Ages: 9 Years to 20 Years · Sex: All (male and female) · 10 locations
• A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
  NCT06717698 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 147 locations
• A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes
  NCT07415954 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 63 locations
• A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes
  NCT07668388 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 70 locations
• A Research Study to Investigate the Efficacy and Safety of HRS9531 Tablets in Participants With Type 2 Diabetes Mellitus
  NCT07599410 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 2 locations
• A Study of Apabetalone in Subjects With Long -COVID
  NCT06590324 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus
  NCT07340320 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 48 locations
• A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus
  NCT07303803 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 17 locations
• A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin
  NCT07109700 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
  NCT06897475 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 60 locations
• A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes
  NCT06924320 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
  NCT07215559 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 42 locations
• A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity
  NCT07724340 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus
  NCT07465224 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
  NCT05824975 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 22 locations
• A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
  NCT07589608 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 40 locations
• A Three-part First-in-human Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB-UCN2 in Healthy Lean and Obese Participants and Participants With T2D
  NCT07702890 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Trial Comparing Efficacy, Tolerability, and Safety of GZR101 Injection Once Daily (OD) and GZR33-70 Injection OD
  NCT06558708 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes
  NCT06820281 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Canagliflozin Targeting Vascular Inflammation
  NCT05427084 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes
  NCT05153070 · Phase: Phase 2 · Ages: 16 Years to 45 Years · Sex: All (male and female) · 1 location
• DETERMINE: Detemir vs NPH
  NCT05124457 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Dapansutrile in Diabetes and Diabetes-Related Complications - Dapan-Dia
  NCT06047262 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 6 locations
• Denosumab for Type 1 Diabetes
  NCT06524960 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 50 Years · Sex: All (male and female) · 3 locations
• Doxycycline in Type II Diabetes
  NCT06329882 · Phase: Phase 1, Phase 2 · Ages: 40 Years to 60 Years · Sex: All (male and female) · 1 location
• Effect of Melatonin in Patients With Diabetic Peripheral Neuropathy
  NCT07036796 · Phase: Phase 2 · Ages: 40 Years to 75 Years · Sex: All (male and female) · 1 location
• Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD)
  NCT05469659 · Phase: Phase 2 · Ages: 20 Years and older · Sex: All (male and female) · 1 location
• Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus
  NCT07282743 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 21 locations
• Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 Diabetes
  NCT06791291 · Phase: Phase 2 · Ages: 1 Year to 34 Years · Sex: All (male and female) · 11 locations
• Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.
  NCT06810726 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 2 locations
• Evaluation of Fuling Yunhua Granules and Dihuang Baoyuan Granules in Drug Naive Type 2 Diabetes Patients
  NCT06575478 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Exercise and Intranasal Insulin in Type 2 Diabetes
  NCT07675499 · Phase: Phase 2, Phase 3 · Ages: 55 Years to 80 Years · Sex: All (male and female) · 4 locations
• Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study
  NCT06906081 · Phase: Phase 2 · Ages: 40 Years and older · Sex: All (male and female) · 2 locations
• Food Effect, Efficacy and Safety of MKP10241 in Healthy and Obese Adult Participants, With and Without Diabetes
  NCT07098663 · Phase: Phase 2 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 1 location
• HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes
  NCT07546929 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 25 locations
• Implementing Food Referrals for Equity and Sustained Health
  NCT06661538 · Phase: Phase 2 · Ages: 5 Years and older · Sex: All (male and female) · 2 locations
• Improving Coronary Vascular Health in Women
  NCT06843902 · Phase: Phase 2 · Ages: 45 Years to 75 Years · Sex: Female · 1 location
• Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)
  NCT07029009 · Phase: Phase 2 · Ages: 10 Years and older · Sex: All (male and female) · 1 location
• Low-Dose Pioglitazone in Patients With NASH (AIM 2)
  NCT04501406 · Phase: Phase 2 · Ages: 21 Years to 75 Years · Sex: All (male and female) · 2 locations
• MANAGe-DM: Novel Nurse Case Management to Improve Diabetes Outcomes in Formerly Incarcerated Black Men
  NCT06031428 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• NAD Augmentation in Diabetes Kidney Disease
  NCT05759468 · Phase: Phase 2 · Ages: 30 Years and older · Sex: All (male and female) · 1 location
• Olive Leaf Extracts in the Control of Diabet
  NCT05605704 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 100 Years · Sex: All (male and female) · 1 location
• Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye
  NCT02846571 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus
  NCT06964087 · Phase: Phase 2 · Ages: 18 Years to 50 Years · Sex: All (male and female) · 5 locations
• Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes
  NCT07167693 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus
  NCT07801820 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy
  NCT07502508 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 17 locations
• Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets
  NCT07502495 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 18 locations
• Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG
  NCT07216391 · Phase: Phase 2 · Ages: 4 Years to 34 Years · Sex: All (male and female) · 6 locations
• Polypill for Prevention of Cardiomyopathy
  NCT06143566 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 100 Years · Sex: All (male and female) · 1 location
• Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy in Diabetic Nephropathy Patients: A Clinical Trial
  NCT07396155 · Phase: Phase 1, Phase 2 · Ages: 30 Years to 65 Years · Sex: All (male and female) · 1 location
• Safety and Efficacy of OCN19-overexpressed Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Refractory Type 2 Diabetes Mellitus
  NCT06727721 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes Mellitus
  NCT07563699 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 64 Years · Sex: All (male and female) · 1 location
• Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus
  NCT05268237 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes
  NCT06435156 · Phase: Phase 2 · Ages: 18 Years to 84 Years · Sex: All (male and female) · 34 locations
• Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
  NCT05267626 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations
• Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease
  NCT07271186 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 58 locations
• Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus
  NCT07527650 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 15 locations
• Taurine Effect on Glycemic, Lipidic and Inflammatory Profile in Individuals With Type 2 Diabetes
  NCT04874012 · Phase: Phase 2 · Ages: 30 Years to 80 Years · Sex: All (male and female) · 1 location
• The Effect of Alpha Lipoid Acid and Vitamin B Preparation on Diabetic Polyneuropathy in Type 2 Diabetes Mellitus Patient
  NCT06568185 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes
  NCT06976619 · Phase: Phase 2 · Ages: 25 Years to 70 Years · Sex: All (male and female) · 1 location
• The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction
  NCT05499702 · Phase: Phase 2 · Ages: 25 Years to 65 Years · Sex: All (male and female) · 1 location
• The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients
  NCT05938712 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• To Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
  NCT06647550 · Phase: Phase 2 · Ages: 19 Years to 75 Years · Sex: All (male and female) · 1 location
• Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
  NCT07296484 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 61 locations
• Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus
  NCT07374328 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• hUC-MSC-Exosomes for T2DM - Safety & Efficacy
  NCT07693036 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location

Common questions

What does Phase 2 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.